If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 8 of 8
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Objective
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors
Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer,
Kidney,
Other Skin,
Thoracic Cancers,
Sarcoma,
Gastrointestinal Cancers,
Cervix,
Prostate and Urologic Cancers,
Other Gynecologic,
Breast Cancers,
Ovary,
Gynecologic Cancers,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Endocrine Cancers,
Melanoma, Skin,
Eye/Orbital Cancers,
Skin Cancers
A Randomized Phase II Study of Amivantamab and Hyaluronidase Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Objective
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Protocol No
SWOG-SN2426
Categories
A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Other Skin,
Other Respiratory,
Colorectal,
Pancreas/Liver,
Skin Cancers,
Other Gynecologic,
Other Gastrointestinal,
Ovary,
Prostate,
Thoracic Cancers,
Gastrointestinal Cancers,
Sarcoma,
Uterine,
Kidney,
Gynecologic Cancers,
Breast Cancers,
Eye/Orbital Cancers,
Head and Neck Cancers,
Other Urologic,
Endocrine Cancers,
Prostate and Urologic Cancers
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
Objective
A Phase 1 study of BG-75098 alone and in combination with BGB-43395 and/or Fulvestrant in Patients with Advanced Solid Tumors.
Protocol No
BEONE-BG-75098-101
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Other Respiratory,
Other Skin,
Pancreas/Liver,
Prostate,
Other Gynecologic,
Colorectal,
Skin Cancers,
Gynecologic Cancers,
Bladder,
Lung,
Other Gastrointestinal,
Esophagus,
Breast Cancers,
Esophagus,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Sarcoma,
Lip, Oral Cavity and Pharynx,
Thoracic Cancers,
Head and Neck Cancers